HPPH

Research use only, not for human use.

HPPH (Photochlor) is a second-generation photosensitizer. It is used as photodynamic therapy (PDT) agent.

HPPH (Photochlor) is a second-generation photosensitizer. It is used as photodynamic therapy (PDT) agent.(In Vitro):Fluorescence image of 4T1 cells incubated with 0.49 μg/mL GO-PEG, 1 μM HPPH (free HPPH) or equivalent amount of GO-PEG-HPPH (1 μM HPPH and 0.49 μg/mL GO-PEG) after 24 h. The cellular uptake of GO-PEG-HPPH and HPPH is investigated with 4T1 murine mammary cancer cells. The cells are incubated with GO-PEG-HPPH and free HPPH at equivalent HPPH concentration (1 μM) for 24 h and then observed with a confocal microscope. Cells treated with GO-PEG-HHPH shows stronger fluorescence signal than those treated with free HPPH. In fact, the fluorescence of HPPH is rather weak. (In Vivo):Tumors are treated with an immune-enhancing PDT regimen followed by a tumor-controlling PDT regimen can leads to enhancement of anti-tumor immunity, while retaining effective control of primary tumor growth. To test this hypothesis, a combination treatment regimen is devised in which Colo26-HA tumor-bearing BALB/c mice are treated with a HPPH-PDT regimen known to lead to enhanced anti-tumor immunity (0.4 μmoles/kg HPPH followed 18 h later by illumination with 665 nm light for a total dose of 48 J/cm2). Following illumination, mice are rested for 9 days; on the ninth day, mice are injected with HPPH. On day 10 following the first treatment, tumors are treated with a tumor control treatment regimen (illumination with 665 nm light for a total dose of 132 J/cm2 given).

Fluorescence image of 4T1 cells incubated with 0.49 μg/mL GO-PEG, 1 μM HPPH (free HPPH) or equivalent amount of GO-PEG-HPPH (1 μM HPPH and 0.49 μg/mL GO-PEG) after 24 h. The cellular uptake of GO-PEG-HPPH and HPPH is investigated with 4T1 murine mammary cancer cells. The cells are incubated with GO-PEG-HPPH and free HPPH at equivalent HPPH concentration (1 μM) for 24 h and then observed with a confocal microscope. Cells treated with GO-PEG-HHPH shows stronger fluorescence signal than those treated with free HPPH. In fact, the fluorescence of HPPH is rather weak.

Tumors are treated with an immune-enhancing PDT regimen followed by a tumor-controlling PDT regimen can leads to enhancement of anti-tumor immunity, while retaining effective control of primary tumor growth. To test this hypothesis, a combination treatment regimen is devised in which Colo26-HA tumor-bearing BALB/c mice are treated with a HPPH-PDT regimen known to lead to enhanced anti-tumor immunity (0.4 μmoles/kg HPPH followed 18 h later by illumination with 665 nm light for a total dose of 48 J/cm2). Following illumination, mice are rested for 9 days; on the ninth day, mice are injected with HPPH. On day 10 following the first treatment, tumors are treated with a tumor control treatment regimen (illumination with 665 nm light for a total dose of 132 J/cm2 given).

Photochlor

Others

Other Targets

Others

——

——

149402-51-7

636.82

C39H48N4O4

>98% (HPLC)

DMSO:50 mg/mL (78.52 mM; Need ultrasonic);H2O:< 0.1 mg/mL (insoluble)

OC(CC[C@@H]([C@@H]1C)/C2=C(C3)/C4=C(C(C)=C(/C=C5C(CC)=C(C)C(/C=C6N/C(C(C)=C\6C(C)OCCCCCC)=C\C1=N2)=N/5)N4)C3=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years